Shenzhen Hepalink Pharmaceutical Group Co

Shenzhen Hepalink Pharmaceutical Group Co., a Pharmaceutical Preparation Manufacturing company headquartered in China, reported its latest carbon emissions for 2025. The company's Scope 1 emissions were approximately 13,482,800 kg CO2e, and its Scope 2 emissions were about 36,787,700 kg CO2e. For 2024, Shenzhen Hepalink's Scope 1 emissions were around 13,689,300 kg CO2e, and Scope 2 emissions were approximately 33,329,700 kg CO2e.

Looking back, in 2023, the company's Scope 1 emissions stood at roughly 24,672,900 kg CO2e, with Scope 2 emissions at about 31,201,200 kg CO2e. In 2022, Scope 1 emissions were around 24,355,200 kg CO2e, and Scope 2 emissions were approximately 33,994,200 kg CO2e. The company reported Scope 1 emissions of about 25,352,500 kg CO2e and Scope 2 emissions of approximately 40,527,100 kg CO2e for 2021. For 2020, Shenzhen Hepalink's total disclosed emissions (Scope 1 and 2) were around 56,441,900 kg CO2e, comprising approximately 19,556,900 kg CO2e for Scope 1 and about 36,885,000 kg CO2e for Scope 2. The company consistently discloses Scope 1 and Scope 2 emissions but has not reported Scope 3 emissions.

Shenzhen Hepalink Pharmaceutical Group Co. has no publicly available reduction targets or climate pledges at this time. All emissions data is directly reported by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. and is not cascaded from a parent organization.